Anna Palau de Miguel

About me
Publications
CV
Public outreach and news

Research

I analyze clinical and genome-wide genetic, transcriptomic and epigenetic data in order to find new therapies (epigenetic and immunotherapies) for acute myeloid leukemia (AML) based on the genetic and epigenetic background of the patient. Moreover, I study the establishment of the leukemogenic pattern using an AML inducible pluripotent stem cell (AML-iPSC) model. I am keen on combining computational analyses with experimental validations.

Articles

Article: LEUKEMIA. 2023;37(9):1830-1841
Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells
Palau A; Segerberg F; Lidschreiber M; Lidschreiber K; Naughton AJ; Needhamsen M; Jung LA; Jagodic M; Cramer P; Lehmann S; Carlsten M; Lennartsson A
Article: BLOOD ADVANCES. 2021;5(4):1003-1016
Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML
Mareschal S; Palau A; Lindberg J; Ruminy P; Nilsson C; Bengtzen S; Engvall M; Eriksson A; Neddermeyer A; Marchand V; Jansson M; Bjorklund M; Jardin F; Rantalainen M; Lennartsson A; Cavelier L; Gronberg H; Lehmann S
Article: EPIGENETICS. 2020;15(6-7):702-714
A regulatory role for CHD2 in myelopoiesis
Varnoosfaderani FS; Palau A; Dong W; Persson J; Durand-Dubief M; Svensson JP; Lennartsson A
Article: ONCOTARGET. 2017;8(70):115002-115017
Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes
Palau A; Garz A-K; Diesch J; Zwick A; Malinverni R; Valero V; Lappin K; Casquero R; Lennartsson A; Zuber J; Navarro T; Mills KI; Goetze KS; Buschbeck M
Article: GENES CHROMOSOMES AND CANCER. 2017;56(3):243-252
Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia.
Palau A; Mallo M; Palomo L; Rodríguez-Hernández I; Diesch J; Campos D; Granada I; Juncà J; Drexler HG; Solé F; Buschbeck M
Article: STEM CELL REPORTS. 2016;7(4):602-618
Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency.
Muñoz-López A; Romero-Moya D; Prieto C; Ramos-Mejía V; Agraz-Doblas A; Varela I; Buschbeck M; Palau A; Carvajal-Vergara X; Giorgetti A; Ford A; Lako M; Granada I; Ruiz-Xivillé N; Rodríguez-Perales S; Torres-Ruíz R; Stam RW; Fuster JL; Fraga MF; Nakanishi M; Cazzaniga G; Bardini M; Cobo I; Bayon GF; Fernandez AF; Bueno C; Menendez P
Article: PLOS GENETICS. 2014;10(12):e1004851
A Cbx8-containing polycomb complex facilitates the transition to gene activation during ES cell differentiation.
Creppe C; Palau A; Malinverni R; Valero V; Buschbeck M
Article: NATURE COMMUNICATIONS. 2014;5:3608
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect.
Lopez-Serra P; Marcilla M; Villanueva A; Ramos-Fernandez A; Palau A; Leal L; Wahi JE; Setien-Baranda F; Szczesna K; Moutinho C; Martinez-Cardus A; Heyn H; Sandoval J; Puertas S; Vidal A; Sanjuan X; Martinez-Balibrea E; Viñals F; Perales JC; Bramsem JB; Ørntoft TF; Andersen CL; Tabernero J; McDermott U; Boxer MB; Vander Heiden MG; Albar JP; Esteller M
Article: EPIGENETICS. 2014;9(3):468-475
First Barcelona Conference on Epigenetics and Cancer.
Palau A; Perucho M; Esteller M; Buschbeck M

All other publications

Corrigendum: NATURE COMMUNICATIONS. 2016;7:13467
Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect.
Lopez-Serra P; Marcilla M; Villanueva A; Ramos-Fernandez A; Palau A; Leal L; Wahi JE; Setien-Baranda F; Szczesna K; Moutinho C; Martinez-Cardus A; Heyn H; Sandoval J; Puertas S; Vidal A; Sanjuan X; Martinez-Balibrea E; Viñals F; Perales JC; Bramsem JB; Ørntoft TF; Andersen CL; Tabernero J; McDermott U; Boxer MB; Vander Heiden MG; Albar JP; Esteller M
Review: CLINICAL EPIGENETICS. 2016;8:71
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers.
Diesch J; Zwick A; Garz A-K; Palau A; Buschbeck M; Götze KS

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2024-2025
Research Specialist, Department of Medicine, Huddinge, Karolinska Institutet, 2024-2024

Research

Articles

All other publications

Employments

News from KI

Events from KI